2023 ASCO Public Disclosures

The molecules presented are investigational. Safety and efficacy have not been established.

SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study

Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).

GNC-038, a tetra-specific antibody, in patients with R/R Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia: Phase 1 study design and rationale